Evidence map›Paper›PMID 26312237›Full record

ArticleJournal of nephropathology2015

Clinical and biochemical investigation of male patients exhibiting membranous cytoplasmic bodies in biopsied kidney tissues; a pitfall in diagnosis of Fabry disease.

Hitoshi Sakuraba, Takahiro Tsukimura, Toshie Tanaka, Tadayasu Togawa, Naoki Takahashi, Daisuke Mikami, Sachiko Wakai, Yasuhiro Akai

Open access · greenAbstract readCase Reports
In one paragraph

Article in Journal of nephropathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Zebra bodies in hydroxychloroquine-naïve class V lupus nephritis.Clinical and experimental nephrology · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Hitoshi SakurabaDepartment of Clinical Genetics, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan.
Takahiro TsukimuraDepartmentof Functional Bioanalysis, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan.
Toshie TanakaDepartment of Clinical Genetics, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan.
Tadayasu TogawaDepartmentof Functional Bioanalysis, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan.
Naoki TakahashiDivision of Nephrology, Department of General Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Fukui, Japan.
Daisuke MikamiDivision of Nephrology, Department of General Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Fukui, Japan.
Sachiko WakaiDivision of Nephrology, Department of Internal Medicine, Ohkubo Hospital, Tokyo Metropolitan Health and Medical Treatment Corporation, Shinjuku, Tokyo, Japan.
Yasuhiro AkaiThe 1st Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan.
Meiji Pharmaceutical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe existence of membranous cytoplasmic bodies in biopsied kidney tissues is one of the important findings when considering Fabry disease as the first choice diagnosis. However, there are possible acquired lysosomal diseases associated with pharmacological toxicity, although less attention has been paid to them. CASE PRESENTATION: We experienced 3 male patients presenting with proteinuria and specific pathological changes strongly suggesting Fabry disease. We sought detailed clinical and biochemical information to avoid a wrong diagnosis. The patients were examined clinically and pathologically, and plasma α-galactosidase A (GLA) activity and the globotriaosylsphingosine (lyso-Gb3) concentrations were measured. Electron microscopic examination revealed numerous membranous inclusion bodies in podocytes, and biochemical analysis revealed normal GLA activity and a normal lyso-Gb3 level in plasma, showing that they did not have Fabry disease. They suffered from hyperlipidemia, myeloma, or lupus nephritis. They had received pitavastatin calcium, clarithromycin, loxoprofen and/or prednisolone, and there was no medication history of cationic amphiphilic drugs.

conclusionsIn this case series, the etiology of the inclusions was not clarified. However, these cases indicate that careful attention should be paid on diagnosis of patients exhibiting inclusion bodies in kidney cells, and it is important to confirm their past and present illnesses, and medication history as well as to measure the GLA activity and lyso-Gb3 level.

Indexed as

Acquired lysosomal diseaseFabry diseaseGlobotriaosylsphingosineInclusion bodyα-Galactosidase A

Identifiers

PMID26312237
PMCPMC4544560
OpenAlexW844461635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.